OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record

• Outlook Therapeutics plans to resubmit its Biologics License Application (BLA) for the treatment in June 2026. 
• The treatment has already been approved in the European Union and the United Kingdom.
• Four analysts have a 12-month price target of $4.17, marking nearly 450% increase based on Wednesday’s closing price.

Outlook Therapeutics (OTLK) share price soared 140% on Thursday and was on-track for its best week since listing, as investors continued to cheer FDA's easing on the requirements for potential approval of its eye disease drug Lytenava. 

Outlook Therapeutics on Tuesday had said the FDA granted its appeal following a Formal Dispute Resolution (FDR) process related to its eye disease drug Lytenava. The FDA concluded that the company had provided sufficient evidence supporting the treatment’s effectiveness for neovascular age-related macular degeneration, also known as wet AMD.

Following the decision, Outlook Therapeutics said it plans to resubmit its Biologics License Application (BLA) for the treatment in June 2026. The company expects the filing to receive a Class 1 review, with a regulatory decision possible within 60 days after resubmission.

The company held an FDR meeting in April to discuss the regulatory pathway for its eye disease treatment. The meeting followed an FDA Type A meeting regarding the Complete Response Letter issued for the drug’s application for wet AMD.

OTLK Directors Buy Shares 

OTLK, in an SEC filing announced on Wednesday, that Randy H. Thurman, a director at Outlook Therapeutics, bought 5,000 shares at a price of $0.429 per share. 

Three other company directors, in addition to Thurman, also bought the company’s class A shares on Wednesday. 

Outlook Therapeutics also recently successfully completed a registered direct offering, raising approximately $5 million by selling over 16 million shares of common stock at $0.31 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction. 

OTLK Retail View 

Retail sentiment on Stocktwits was “extremely bullish” with “extremely high” message volumes. 

One user highlighted $50,000 worth of insider buying in the stock leading to bullishness. 

OTLK stock has lost nearly 54% over the past 12 months. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Editor's Note: The story has been updated to clarify that the company won an appeal with the FDA and not an approval for Lytenava.